Skip to main content
. Author manuscript; available in PMC: 2010 Jan 14.
Published in final edited form as: Behav Brain Res. 2006 Dec 21;178(2):190–199. doi: 10.1016/j.bbr.2006.12.020

Figure 4.

Figure 4

Mean (±S.E.M.) number of locomotor activity counts during the 30 min session for rats that received acute treatment with 0.5 mg/kg haloperidol plus saline vehicle, and 0.5 mg/kg haloperidol plus various doses of MSX-3 injected intracranially (2.5 and 5.0 µg per side). MSX-3 administered to haloperidol-treated rats significantly increased locomotion relative to treatment with haloperidol alone (*p < 0.05). (A) MSX-3 injected into nucleus accumbens core (experiment 3A; 0.5 mg/kg haloperidol plus saline vehicle (n = 11), and 0.5 mg/kg haloperidol plus 2.5 (n =11) and 5.0 (n = 12) µg MSX-3 per side). (B) MSX-3 injected into nucleus accumbens shell (experiment 3B; 0.5 mg/kg haloperidol plus saline vehicle (n =10), and 0.5 mg/kg haloperidol plus 2.5 (n = 12) and 5.0 (n = 12) µg MSX-3 per side). (C) MSX-3 injected into VLS (experiment 3C; 0.5 mg/kg haloperidol plus saline vehicle (n = 7), and 0.5 mg/kg haloperidol plus 2.5 (n = 10) and 5.0 (n = 8) µg MSX-3 per side).